Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose…
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the…
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive…
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare…
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE…
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and…
Life sciences platform enhanced to make cognitive assessments easier and more precise BOSTON, July 24, 2024 /PRNewswire/ -- Linus Health, a…
Company's virtual therapeutic programs and proprietary risk stratification algorithm support proactive detection of and intervention for cognitive decline BOSTON, July…
Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression NEW YORK and CHICAGO, July…
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…
